Immix Biopharma, Inc. (IMMX) vs OrthoPediatrics Corp. (KIDS)
A side-by-side comparison of Immix Biopharma, Inc. and OrthoPediatrics Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMMX
Immix Biopharma, Inc.
$9.59HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
KIDS
OrthoPediatrics Corp.
$22.88HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — IMMX vs KIDS
growth of $100 · dividends reinvested · last 5yIMMX +176.0% (+22.5%/yr)KIDS -59.7% (-16.6%/yr)IMMX compounded faster over this window
Log scale — wide-divergence pair
IMMX KIDS
IMMX vs KIDS: by the numbers
- •KIDS is the larger company ($588M vs $522M market cap).
- •Both run net losses; IMMX's is the smaller (0.00% vs -15.72% net margin).
Metrics side by side
Valuation
| Metric | IMMX | KIDS |
|---|---|---|
| P/S ratio | N/A | 2.33 |
| P/B ratio | 2.28 | 1.71 |
Profitability
| Metric | IMMX | KIDS |
|---|---|---|
| Gross margin | 0.00% | 73.65% |
| Operating margin | 0.00% | -9.01% |
| Net margin | 0.00% | -15.72% |
| ROE | -17.44% | -11.56% |
| ROIC | -18.20% | -4.97% |
Growth (annualized)
| Metric | IMMX | KIDS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 23.14% |
| Total return CAGR (5Y) | N/A | -18.40% |
Go deeper
Dig into the metrics
Immix Biopharma ROEOrthoPediatrics ROEImmix Biopharma operating marginOrthoPediatrics operating marginImmix Biopharma revenue growthOrthoPediatrics revenue growthImmix Biopharma free cash flowOrthoPediatrics free cash flow
Immix Biopharma & OrthoPediatrics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.